세계의 당뇨병성 말초신경병증 시장 보고서(2025년)

Diabetic Peripheral Neuropathy Global Market Report 2025

US $ 4,490 ￦ 6,253,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,039,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,824,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

당뇨병성 말초신경병증 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 CAGR 9.1%로 54억 3,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 좌식 생활 습관 증가, 정부 노력과 보조금 증가, 신경 장애 위험 요소의 유병률 증가, 진단 정확도 향상, 조기 발견 및 예방에 대한 지원 확대에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 진단 기술의 발전, 치료 옵션의 혁신, 연구개발 투자 증가, 저침습적 시술의 개발, 공동 연구개발에 대한 관심 증가 등을 들 수 있습니다.

비만 관련 건강 문제의 유병률 증가는 향후 몇 년 동안 당뇨병성 말초신경병증 시장의 성장을 가속할 것으로 예측됩니다. 비만은 과도한 체지방 축적을 특징으로 하는 질환으로 건강을 해치고 만성 질환의 위험을 증가시킬 수 있습니다. 비만과 관련된 건강 문제, 생활습관 변화, 예방 및 치료 솔루션에 대한 수요 증가에 대한 인식이 높아지면서 헬스케어 수요 증가에 기여하고 있습니다. 당뇨병성 말초신경병증은 비만 관련 질환으로 인한 신경 손상에 대한 지식을 제공하고, 환자의 행복과 삶의 질을 향상시키기 위한 표적화된 개입을 가능하게 함으로써 비만 관리에 중요한 역할을 하고 있습니다. 예를 들어, 2024년 3월, 스위스에 본부를 둔 세계보건기구(WHO)는 세계 공중보건에 초점을 맞춘 유엔의 전문기관으로, 2022년 18세 이상 성인의 43%가 과체중으로 분류되고 16%가 비만과 함께 생활하고 있다고 보고했습니다. 또한, 5세 미만 어린이 중 3,700만 명이 과체중이며, 5세에서 19세 사이의 어린이와 청소년은 3억 9,000만 명 이상이 과체중이며, 그 중 1억 6,000만 명이 비만의 영향을 받고 있습니다. 그 결과, 비만과 관련된 건강 문제의 발생률 증가가 당뇨병성 말초신경병증 시장의 성장을 가속하고 있습니다.

당뇨병성 말초신경병증 시장의 주요 기업들은 통증 관리를 개선하고 환자의 삶의 질을 향상시키는 혁신적인 비오피오이드 치료제를 제공하기 위해 NaV1.8 통증 신호 억제제와 같은 기술적 진보를 우선순위로 삼고 있습니다. 매개체인 NaV1.8 나트륨 채널을 차단하는 특수 약물로, 오피오이드에 의존하지 않고도 급성 통증 및 신경병증성 통증을 완화할 수 있습니다. 예를 들어, 2024년 4월 미국 생명공학 기업 버텍스 파마슈티컬스(Vertex Pharmaceuticals Inc.)는 수세트리진 통증 프로그램의 진행 상황을 발표했습니다. 수세트리진은 선택적 NaV1.8 통증 신호 억제제이며, 선행 연구에서 유망한 결과를 보였고, 최근 미국 식품의약국(FDA)으로부터 당뇨병성 말초신경병증 통증 관리를 위한 획기적인 치료제로 지정되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 당뇨병성 말초신경병증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 당뇨병성 말초신경병증 시장 : 성장률 분석
• 세계의 당뇨병성 말초신경병증 시장 실적 : 규모와 성장, 2019-2024
• 세계의 당뇨병성 말초신경병증 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 당뇨병성 말초신경병증 전체 시장(TAM)

제6장 시장 세분화

• 세계의 당뇨병성 말초신경병증 시장 : 질환별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Type 2 당뇨병성 말초신경병증
• Type 1 당뇨병성 말초신경병증
• 세계의 당뇨병성 말초신경병증 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 통증 관리제
• 유전자 치료
• 세계의 당뇨병성 말초신경병증 시장 : 세라피별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 항우울제
• 항경련제
• 세계의 당뇨병성 말초신경병증 시장 : 환자 집단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 성인 환자
• 고령 환자
• 세계의 당뇨병성 말초신경병증 시장 : 2형 당뇨병성 말초신경병증 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 감각신경 장애
• 운동신경 장애
• 자율신경 장애
• 세계의 당뇨병성 말초신경병증 시장 : 1형 당뇨병성 말초신경병증 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 원위 대칭 신경병증
• 단신경병증
• 다발성 근병증

제7장 지역별/국가별 분석

• 세계의 당뇨병성 말초신경병증 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 당뇨병성 말초신경병증 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 당뇨병성 말초신경병증 시장 : 경쟁 구도
• 당뇨병성 말초신경병증 시장 : 기업 개요
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • GlaxoSmithKline plc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Eli Lilly and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Astellas Pharma Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Sun Pharmaceutical Industries Limited
• Lupin Pharmaceuticals Inc.
• Chemie Grunenthal GmbH
• Alkem Laboratories Limited
• Acorda Therapeutics Inc.
• Mitsubishi Tanabe Pharma Corporation
• NeuroMetrix Inc.
• Regenacy Pharmaceuticals Inc.
• Helixmith Co. Ltd.
• Aptinyx Inc.
• WinSanTor Inc.
• Sonnet BioTherapeutics Holdings Inc.
• OLYS Pharma Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 당뇨병성 말초신경병증 시장(2029년) : 새로운 기회를 제공하는 국가
• 당뇨병성 말초신경병증 시장(2029년) : 새로운 기회를 제공하는 부문
• 당뇨병성 말초신경병증 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Diabetic Peripheral Neuropathy (DPN) is a nerve disorder resulting from prolonged high blood sugar levels in individuals with diabetes, causing nerve damage primarily in the legs, feet, arms, and hands. This condition develops due to long-term elevated blood sugar levels, which harm the nerves and blood vessels, leading to impaired nerve function and reduced blood flow to the affected areas.

The primary types of diabetic peripheral neuropathy include type 2 and type 1 diabetic peripheral neuropathy. Type 2 diabetic peripheral neuropathy is a nerve damage condition caused by prolonged high blood sugar levels in individuals with type 2 diabetes, resulting in pain, numbness, and tingling, mainly in the feet and hands. Treatment options encompass pain management drugs and emerging gene therapies, while therapeutic approaches involve the use of antidepressants and anticonvulsants. The affected patient population primarily consists of adult and geriatric individuals.

The diabetic peripheral neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic peripheral neuropathy market statistics, including the diabetic peripheral neuropathy industry global market size, regional shares, competitors with the diabetic peripheral neuropathy market share, detailed diabetic peripheral neuropathy market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic peripheral neuropathy industry. This diabetic peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetic peripheral neuropathy market size has grown strongly in recent years. It will grow from $3.51 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to the expanding geriatric population, the increasing prevalence of diabetes, rising healthcare expenditure, growing awareness of diabetic complications, and the enhancement of healthcare infrastructure.

The diabetic peripheral neuropathy market size is expected to see strong growth in the next few years. It will grow to $5.43 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the rise in sedentary lifestyles, increased government initiatives and funding, the growing prevalence of neuropathy risk factors, improved diagnostic accuracy, and expanding support for early detection and prevention. Key trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, increased investment in research and development, the development of minimally invasive procedures, and a heightened focus on collaborative research and development.

The rising prevalence of obesity-related health issues is anticipated to drive the expansion of the diabetic peripheral neuropathy market in the coming years. Obesity is a medical condition characterized by excessive body fat accumulation, which can impair health and increase the risk of chronic diseases. The growing awareness of obesity-related health concerns, lifestyle changes, and the increasing need for preventive and treatment solutions have contributed to greater healthcare demand. Diabetic peripheral neuropathy plays a critical role in obesity management by offering insights into nerve damage caused by obesity-related conditions, enabling targeted interventions to enhance patient well-being and quality of life. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations focused on global public health, reported that in 2022, 43% of adults aged 18 and over were classified as overweight, while 16% were living with obesity. Additionally, 37 million children under the age of five were overweight, and among children and adolescents aged 5 to 19 years, over 390 million were overweight, including 160 million affected by obesity. As a result, the increasing incidence of obesity-related health issues is driving growth in the diabetic peripheral neuropathy market.

Leading companies in the diabetic peripheral neuropathy market are prioritizing technological advancements, such as NaV1.8 pain signal inhibitors, to offer innovative non-opioid treatments that improve pain management and enhance patients' quality of life. A NaV1.8 pain signal inhibitor is a specialized drug that blocks the NaV1.8 sodium channel, a key mediator of pain signals in sensory neurons, to provide relief from acute and neuropathic pain without relying on opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, announced progress in its suzetrigine pain program, including the initiation of a Phase 3 pivotal program for treating pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has demonstrated promising results in earlier studies and recently received breakthrough therapy designation from the Food and Drug Administration (FDA), a US-based federal agency, for diabetic peripheral neuropathy pain management.

In December 2024, ElectroCore, Inc., a US-based medical technology company, acquired NeuroMetrix, Inc. for $26 million. This acquisition aims to expand ElectroCore's bioelectronic health and wellness portfolio by integrating NeuroMetrix's Quell platform. The strategic move is intended to enhance non-invasive, technology-driven solutions for managing chronic pain and addressing conditions such as diabetic peripheral neuropathy while improving technological capabilities and increasing market reach. NeuroMetrix, Inc. is a US-based healthcare company specializing in the development and commercialization of products designed to diagnose and treat diabetic peripheral neuropathy.

Major players in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grunenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.

North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic peripheral neuropathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic peripheral neuropathy market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical treatment services, and physical and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic peripheral neuropathy market also includes sales of pharmaceuticals, medical devices, nutritional supplements, and physical therapy tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Peripheral Neuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic peripheral neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic peripheral neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic peripheral neuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease: Type 2 Diabetic Peripheral Neuropathy; Type 1 Diabetic Peripheral Neuropathy
• 2) By Treatment: Pain Management Drugs; Gene Therapies
• 3) By Therapy: Antidepressants; Anticonvulsants
• 4) By Patient Population: Adult Patients; Geriatric Patients
• Subsegments:
• 1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy; Motor Neuropathy; Autonomic Neuropathy
• 2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyradiculopathy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc.; Eli Lilly and Company; Astellas Pharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Peripheral Neuropathy Market Characteristics

3. Diabetic Peripheral Neuropathy Market Trends And Strategies

4. Diabetic Peripheral Neuropathy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Peripheral Neuropathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Peripheral Neuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Peripheral Neuropathy Market Growth Rate Analysis
• 5.4. Global Diabetic Peripheral Neuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Peripheral Neuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Peripheral Neuropathy Total Addressable Market (TAM)

6. Diabetic Peripheral Neuropathy Market Segmentation

• 6.1. Global Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetic Peripheral Neuropathy
• Type 1 Diabetic Peripheral Neuropathy
• 6.2. Global Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Management Drugs
• Gene Therapies
• 6.3. Global Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants
• Anticonvulsants
• 6.4. Global Diabetic Peripheral Neuropathy Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult Patients
• Geriatric Patients
• 6.5. Global Diabetic Peripheral Neuropathy Market, Sub-Segmentation Of Type 2 Diabetic Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sensory Neuropathy
• Motor Neuropathy
• Autonomic Neuropathy
• 6.6. Global Diabetic Peripheral Neuropathy Market, Sub-Segmentation Of Type 1 Diabetic Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Distal Symmetric Neuropathy
• Mononeuropathy
• Polyradiculopathy

7. Diabetic Peripheral Neuropathy Market Regional And Country Analysis

• 7.1. Global Diabetic Peripheral Neuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Peripheral Neuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Peripheral Neuropathy Market

• 8.1. Asia-Pacific Diabetic Peripheral Neuropathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Peripheral Neuropathy Market

• 9.1. China Diabetic Peripheral Neuropathy Market Overview
• 9.2. China Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Peripheral Neuropathy Market

• 10.1. India Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Peripheral Neuropathy Market

• 11.1. Japan Diabetic Peripheral Neuropathy Market Overview
• 11.2. Japan Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Peripheral Neuropathy Market

• 12.1. Australia Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Peripheral Neuropathy Market

• 13.1. Indonesia Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Peripheral Neuropathy Market

• 14.1. South Korea Diabetic Peripheral Neuropathy Market Overview
• 14.2. South Korea Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Peripheral Neuropathy Market

• 15.1. Western Europe Diabetic Peripheral Neuropathy Market Overview
• 15.2. Western Europe Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Peripheral Neuropathy Market

• 16.1. UK Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Peripheral Neuropathy Market

• 17.1. Germany Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Peripheral Neuropathy Market

• 18.1. France Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Peripheral Neuropathy Market

• 19.1. Italy Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Peripheral Neuropathy Market

• 20.1. Spain Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Peripheral Neuropathy Market

• 21.1. Eastern Europe Diabetic Peripheral Neuropathy Market Overview
• 21.2. Eastern Europe Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Peripheral Neuropathy Market

• 22.1. Russia Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Peripheral Neuropathy Market

• 23.1. North America Diabetic Peripheral Neuropathy Market Overview
• 23.2. North America Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Peripheral Neuropathy Market

• 24.1. USA Diabetic Peripheral Neuropathy Market Overview
• 24.2. USA Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Peripheral Neuropathy Market

• 25.1. Canada Diabetic Peripheral Neuropathy Market Overview
• 25.2. Canada Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Peripheral Neuropathy Market

• 26.1. South America Diabetic Peripheral Neuropathy Market Overview
• 26.2. South America Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Peripheral Neuropathy Market

• 27.1. Brazil Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Peripheral Neuropathy Market

• 28.1. Middle East Diabetic Peripheral Neuropathy Market Overview
• 28.2. Middle East Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Peripheral Neuropathy Market

• 29.1. Africa Diabetic Peripheral Neuropathy Market Overview
• 29.2. Africa Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Peripheral Neuropathy Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Peripheral Neuropathy Market Competitive Landscape
• 30.2. Diabetic Peripheral Neuropathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Peripheral Neuropathy Market Other Major And Innovative Companies

• 31.1. Biogen Inc.
• 31.2. Vertex Pharmaceuticals Incorporated
• 31.3. Sun Pharmaceutical Industries Limited
• 31.4. Lupin Pharmaceuticals Inc.
• 31.5. Chemie Grunenthal GmbH
• 31.6. Alkem Laboratories Limited
• 31.7. Acorda Therapeutics Inc.
• 31.8. Mitsubishi Tanabe Pharma Corporation
• 31.9. NeuroMetrix Inc.
• 31.10. Regenacy Pharmaceuticals Inc.
• 31.11. Helixmith Co. Ltd.
• 31.12. Aptinyx Inc.
• 31.13. WinSanTor Inc.
• 31.14. Sonnet BioTherapeutics Holdings Inc.
• 31.15. OLYS Pharma Inc.

32. Global Diabetic Peripheral Neuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Peripheral Neuropathy Market

34. Recent Developments In The Diabetic Peripheral Neuropathy Market

35. Diabetic Peripheral Neuropathy Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Peripheral Neuropathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Peripheral Neuropathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Peripheral Neuropathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료